MOTS-c Neutralised MRSA in Mice: A 2026 eLife Report

A paper in eLife dated 18 August 2026 makes a claim that sounds implausible until you read the reasoning: the human immune system is partly encoded by mitochondrial DNA, and MOTS-c is the evidence.

The authors report identifying a host defence peptide encoded in the human mitochondrial genome, which they suggest derives from the primordial proto-mitochondrial bacteria. If that holds, it is a first. The immune system has been treated as exclusively nuclear-encoded.

This is a second track for a compound most readers know from metabolism. We covered the other one recently, in a review that placed it among the sORF-encoded microproteins alongside Humanin. Nothing here concerns human use. MOTS-c is supplied as research material only.

What a host defence peptide is, and why MOTS-c qualifies

Host defence peptides, also called antimicrobial peptides, are short molecules that kill microbes directly and also modulate the immune response. They tend to share a chemistry: amphipathic, meaning they have both water-loving and fat-loving faces, and cationic, meaning they carry positive charge. That combination lets them insert into and disrupt bacterial membranes, which are negatively charged, while largely sparing host cells.

The families usually named in this category, the defensins and the cathelicidins, are encoded in the nuclear genome. That is the assumption the paper sets out to unsettle.

The authors describe MOTS-c as amphipathic and cationic, and state that its functions are consistent with the peptide chemistry and functions of known host defence peptides. That is the structural argument underneath the claim, and it is worth noticing that it is an argument from chemistry first and function second, which is the right order.

Where the name comes from

The abbreviation is not decorative. MOTS-c stands for mitochondrial open reading frame from the 12S rRNA type-c, which locates the peptide precisely: it is translated from a short reading frame inside the gene for the small subunit ribosomal RNA of the mitochondrion.

That matters for the evolutionary argument the authors make. Mitochondria descend from bacteria, so a bacteria-killing peptide encoded in mitochondrial DNA is, on their reading, a survival of the organelle’s own ancestry rather than a coincidence.

The antibacterial results

MOTS-c targeted Escherichia coli and methicillin-resistant Staphylococcus aureus, according to the authors, in part by targeting their membranes using its hydrophobic and cationic domains.

The result that will get quoted is from a mouse model of acute peritonitis, where the authors report that MOTS-c fully neutralised MRSA infectivity.

Two things are worth holding onto about that sentence. It is a mouse model of a specific infection, not a treatment result. And “neutralised infectivity” is the authors’ phrasing for what they measured, which is not the same as a survival or cure endpoint in a clinical sense.

The immune reprogramming results

The second half of the paper is arguably the more interesting one.

In human monocytes, the authors report that interferon gamma, lipopolysaccharide, and differentiation signals each induced expression of endogenous MOTS-c. In other words, the cell makes more of the peptide when it detects infection or inflammatory signalling. That is what you would expect of a defence molecule and not what you would expect of a purely metabolic one.

Applied from outside during primary mouse monocyte differentiation, MOTS-c reprogrammed the cells into macrophages with distinct transcriptomic signatures related to antigen presentation and interferon signalling. Those macrophages showed enhanced bacterial clearance and a shifted metabolism, the authors report.

The metabolic shift is the point where the two MOTS-c literatures meet. Macrophage function and macrophage metabolism are tightly coupled, so a peptide with metabolic activity turning up as an immune regulator is less of a coincidence than it first appears.

Three things to check before citing this

It is a reviewed preprint that took time to land. The copyright line reads 2023 and the article identifier is an eLife Reviewed Preprint. The work has been in that pipeline for a while and the indexed version appeared now. The findings are not three days old, whatever the index date suggests.

The senior author declares a commercial interest. The corresponding author is listed as a consultant and shareholder of CohBar, Inc, a company built around mitochondrial-derived peptides. The other authors declare no competing interests. This is disclosed in the paper and is context, not an accusation.

The evidence is cell and mouse work. Human monocytes in culture, mouse monocytes, a mouse peritonitis model. There is no human infection data.

Why this matters for peptide research

If the finding holds, the interesting consequence is not a new antibiotic candidate. Host defence peptides have been pursued as antibiotics for decades with limited clinical success, largely because of stability, toxicity and manufacturing problems.

The consequence is conceptual. It means mitochondria, which are already understood to trigger immune responses by releasing their DNA as a danger signal, may also encode active immune effectors. That reframes the organelle from a passive alarm into a participant, and it gives a reason why a peptide from the 12S rRNA reading frame would be inducible by interferon gamma at all.

For laboratories, it also widens what MOTS-c is worth testing for. A compound characterised as metabolic has a certain set of standard assays attached to it: glucose uptake, insulin signalling, mitochondrial respiration. One characterised as a host defence peptide has a different set, including minimum inhibitory concentration work against defined strains, membrane permeabilisation assays, and haemolysis testing to check that the peptide is not disrupting host membranes along with bacterial ones.

Those two assay panels rarely appear in the same laboratory, which is part of why a molecule can sit in one literature for a decade before anyone runs the other set of experiments on it. The eLife paper is what that looks like when someone does.

It also raises a practical question about material. Antibacterial assays are unforgiving about what is actually in the vial, because bacterial growth inhibition can be produced by a range of contaminants that have nothing to do with the peptide being tested. Endotoxin content matters for the immune experiments in particular, since lipopolysaccharide is itself one of the stimuli the authors used to induce MOTS-c expression. A preparation carrying residual endotoxin would confound exactly the readout the paper depends on.

Our MOTS-c reference material documentation covers the identity and purity fields that matter before either kind of assay, and the European research buyer guide covers procurement in the EU.

References

• Rice MC, Imun M, Jung SW, et al. MOTS-c is a mitochondrial-encoded interferon-linked host defense peptide. eLife, 18 August 2026. doi 10.7554/eLife.87615
• Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism, 3 March 2015
• Kim KH, Son JM, Benayoun BA, Lee C. The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress. Cell Metabolism, 4 September 2018

The products referenced on this site are supplied for laboratory research use only. They are not medicines and are not intended for human or veterinary use. This article summarises published research for informational purposes and is not medical advice. Statements about third-party studies belong to their authors.